根治性膀胱切除原位新膀胱术后代谢并发症及处理研究进展

董昊楠; 王海峰; 黄应龙; 施鸿金; 毛岚; 刘毅杰; 王剑松

doi:10.12259/j.issn.2095-610X.S20221229

根治性膀胱切除原位新膀胱术后代谢并发症及处理研究进展

doi: 10.12259/j.issn.2095-610X.S20221229

昆明医科大学第二附属医院泌尿外科，云南省泌尿外科研究所，云南昆明　650101

基金项目: 国家自然科学基金资助项目（82060464）；云南省科技厅科技计划基金资助项目（202001AY070001-163）

详细信息

作者简介:
董昊楠（1996～），男，吉林白山人，在读临床硕士研究生，主要从事泌尿外科肿瘤微创治疗工作

通讯作者:
王剑松，E-mail：jiansongwang@126.com

中图分类号: R737.14
计量
- 文章访问数: 3770
- HTML全文浏览量: 2470
- PDF下载量: 19
- 被引次数: 0
出版历程
- 收稿日期: 2022-08-18
- 网络出版日期: 2022-12-06
- 刊出日期: 2022-12-25

A Review on Metabolic Complications and Management after Radical Cystectomy and Orthotopic Neoblastectomy

Dept. of Urology，The 2nd Affiliate Hospital of Kunming Medical University， Yunnan Institute of Urology，Kunming Yunnan 650101，China

摘要

摘要: 膀胱癌是泌尿系常见的恶性肿瘤之一，可分为非肌层浸润性膀胱癌以及肌层浸润性膀胱癌。根治性膀胱切除术是肌层浸润性膀胱癌的首选治疗方案；原位新膀胱术目前已经成为根治性膀胱切除术后首选的尿流改道方式，因术中需使用不同肠段，术后可能出现不同的代谢相关并发症，这些并发症也成为降低患者术后生活质量的原因之一。现对原位新膀胱术后代谢并发症的主要类型以及处理进展进行综述。
- 膀胱癌 /
- 根治性膀胱全切术 /
- 原位尿流改道 /
- 代谢并发症
Abstract: Bladder cancer is one of the common malignant tumors of urinary system, which can be divided into two categoties, non-muscle-invasive bladder cancer and muscle-invasive bladder cancer. Radical cystectomy is the treatment of choice for muscle-invasive bladder cancer. At present, orthotopic neobasical bladder surgery has become the preferred method of urinary diversion after radical cystectomy. Due to the use of different intestinal segments during surgery, different metabolic complications may occur after surgery, which also become one of the reasons for reducing the quality of life of patients after surgery. This article reviews the main types and management progress of metabolic complications after orthotopic neobasical bladder surgery.
- Bladder cancer /
- Radical cystectomy /
- Orthotopic urinary diversion /
- Metabolic complications

HTML全文

参考文献(30)

[1]	Zheng R,Zhang S,Zeng H,et al. Cancer incidence and mortality in China,2016[J]. Journal of the National Cancer Center,2022,2(1):1-9. doi: 10.1016/j.jncc.2022.02.002
[2]	Witjes J A,Bruins H M,Cathomas R,et al. European association of urology guidelines on muscle-invasive and metastatic bladder cancer:Summary of the 2020 guidelines[J]. Eur Urol,2021,79(1):82-104. doi: 10.1016/j.eururo.2020.03.055
[3]	Joensen U N,Maibom S L,Poulsen A M. Surgical management of muscle invasive bladder cancer:A review of current recommendations[J]. Semin Oncol Nurs,2021,37(1):151104.
[4]	Li K,Lin T,Chinese Bladder Cancer C,et al. Current status of diagnosis and treatment of bladder cancer in China - Analyses of Chinese bladder cancer consortium database[J]. Asian J Urol,2015,2(2):63-69. doi: 10.1016/j.ajur.2015.04.016
[5]	McDougal W S. Metabolic complications of urinary intestinal diversion[J]. Journal of Urology,1992,147(5):1199-1208. doi: 10.1016/S0022-5347(17)37517-1
[6]	Stein R,Rubenwolf P. Metabolic consequences after urinary diversion[J]. Front Pediatr,2014,2:15.
[7]	Mills R D,Studer U E. Metabolic consequences of continent urinary diversion[J]. The Journal of Urology,1999,161(4):1057-1066. doi: 10.1016/S0022-5347(01)61590-8
[8]	Shamsa A. Gastric pouch after simple or radical cystectomy for benign and malignant bladder disease[J]. Nephrourol Mon,2014,6(6):e17890.
[9]	De Toledo A F,da Cunha C E B,Steppe C H,et al. Gastric neobladders:Surgical outcomes of 91 cases using different techniques[J]. Int Braz J Urol,2018,44(5):914-919.
[10]	Koraitim M M,Khalil M R,Ali G A,et al. Micturition after gastrocystoplasty and gastric bladder replacement[J]. The Journal of Urology,1999,161(5):1480-1485. doi: 10.1016/S0022-5347(05)68931-8
[11]	Lin D W,Santucci R A,Mayo M E,et al. Urodynamic evaluation and long-term results of the orthotopic gastric neobladder in men[J]. The Journal of Urology,2000,164(2):356-359.
[12]	Dahl D M, McDougal W S. Use of intestinal segments in urinary diversion[M]. In: Wein AJ. Campbell-Walsh Urology. Philadelphia: Saunders Elsevier, 2007, 2534–2578.
[13]	Hautmann R E,Botto H,Studer U E. How to obtain good results with orthotopic bladder substitution:The 10 commandments[J]. European Urology Supplements,2009,8(9):712-717.
[14]	Muller G,Butea-Bocu M,Brock O,et al. Association between development of metabolic acidosis and improvement of urinary continence after ileal neobladder creation[J]. J Urol,2020,203(3):585-590.
[15]	Kim K H,Yoon H S,Yoon H,et al. Risk factors for developing metabolic acidosis after radical cystectomy and ileal neobladder[J]. PLoS One,2016,11(7):e0158220.
[16]	Qu L G,Lawrentschuk N. Orthotopic neobladder reconstruction:Patient selection and perspectives[J]. Res Rep Urol,2019,11:333-341.
[17]	Herdiman O,Ong K,Johnson L,et al. Orthotopic bladder substitution (neobladder):Part II:Postoperative complications,management,and long-term follow-up[J]. J Wound Ostomy Continence Nurs,2013,40(2):171-180.
[18]	Stein R,Wiesner C,Beetz R,et al. Urinary diversion in children and adolescents with neurogenic bladder:The mainz experience. part II:Continent cutaneous diversion using the Mainz pouch I[J]. Pediatr Nephrol,2005,20(7):926-931. doi: 10.1007/s00467-005-1848-2
[19]	Chang S S,Bochner B H,Chou R,et al. Treatment of non-metastatic muscle-invasive bladder cancer:AUA/ASCO/ASTRO/SUO guideline[J]. J Urol,2017,198(3):552-559. doi: 10.1016/j.juro.2017.04.086
[20]	Bilge M,Adas M,Yesilova A,et al. Osteomalacia as a result of urinary diversion[J]. Acta Endocrinol (Buchar),2017,13(4):491-493. doi: 10.4183/aeb.2017.491
[21]	Richard P O,Bashir S,Riverin B D,et al. Risk of bone fractures following urinary intestinal diversion:A population based study[J]. J Urol,2019,202(2):319-325.
[22]	Hirukawa M,Funakoshi H,Tsukamoto T,et al. Osteomalacia due to a bladder reconstruction performed 35 years previously[J]. Intern Med,2012,51(15):2051-2055. doi: 10.2169/internalmedicine.51.7980
[23]	Cano Megias M,Munoz Delgado E G. Bone and metabolic complications of urinary diversions[J]. Endocrinol Nutr,2015,62(2):100-105.
[24]	Hautmann R . Urinary diversion. World Health Organization (WHO) consensus conference on bladder cancer[J]. Urology,2007,69(1 Suppl):17-49.
[25]	Boucher,Michelle (NURSE),Bryan,et al. Deficiency or dementia? Exploring b12 deficiency after urostomy.[J]. British Journal of Nursing,2015,24(11):594-597. doi: 10.12968/bjon.2015.24.11.594
[26]	Van der Aa F,Joniau S,Van Den Branden M,et al. Metabolic changes after urinary diversion[J]. Adv Urol,2011,2011:764325.
[27]	Reddy M,Kader K. Follow-up management of cystectomy patients[J]. Urol Clin North Am,2018,45(2):241-247. doi: 10.1016/j.ucl.2018.01.001
[28]	Sagalowsky A I,Frenkel E P. Cobalamin profiles in patients after urinary diversion[J]. Journal of Urology,2002,167(4):1696-1700. doi: 10.1016/S0022-5347(05)65180-4
[29]	Sperling C D,Lee D J,Aggarwal S. Urinary diversion:core curriculum 2021[J]. Am J Kidney Dis,2021,78(2):293-304. doi: 10.1053/j.ajkd.2020.12.023
[30]	Roth S,Semjonow A,Waldner M,et al. Risk of bowel dysfunction with diarrhea after continent urinary diversion with ileal and ileocecal segments[J]. Journal of Urology,1995,154(5):1696-1699. doi: 10.1016/S0022-5347(01)66754-5

相关文章(20)

[1]	刘胜, 袁飞, 周红庆, 刘明生, 邹东桓, 李钰, 戴子涵, 陈冠宇, 郭峰. 完全性盆底腹膜重建技术在膀胱全切原位新膀胱术中的疗效分析, 昆明医科大学学报.
[2]	刘玉芹, 杨明莹, 王留芳, 夏斯亚, 李丹娜, 赵喜娟, 王娅. 膀胱癌患者报告结局量表的编制与信效度检验, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20240727
[3]	安义均, 余立丹, 赵美素, 马冬梅, 杨春花, 孔瑶. 膀胱癌溶酶体相关基因的预后模型构建与分析, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20240510
[4]	谢雨晴, 王俊, 吉学碧, 王萍, 王海峰, 李旭敏, 黄麟雅. 输尿管皮肤造口患者尿路感染危险因素及风险评估研究进展, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20231124
[5]	谢峻, 刘绍有, 施鸿金, 毛秋玉, 杨宏. EZH2抑制剂与膀胱癌GC化疗药物联用增敏的作用研究, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20231017
[6]	陈诗, 付什, 谭智勇, 王剑松, 王海峰. 自噬在膀胱癌发展和治疗中的研究进展, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20230503
[7]	顾君, 何泽喜, 栾婷, 王海峰, 王剑松, 丁明霞. 外泌体长链非编码RNA在膀胱癌中的研究进展, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20220110
[8]	严植, 郝金钢, 尚芸芸. VI-RADS评分对膀胱癌精准治疗的价值, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20220322
[9]	李丹娜, 王俊, 杨明莹, 余力锐, 李娜, 杨毅娇. 膀胱癌根治性切除输尿管皮肤造口术尿路造口患者术后生命质量影响因素, 昆明医科大学学报.
[10]	黄宇, 栾婷, 王海峰, 王剑松. 液体活检在监测膀胱癌转移及疗效分析中的研究进展, 昆明医科大学学报.
[11]	杨灿, 巩宇航, 王海峰, 李海皓, 刘靖宇, 王伟, 王剑松, 左毅刚, 陈戬, 詹辉, 丁明霞. 单抗KMP1的体内抑制膀胱癌EJ细胞株成瘤的动物实验, 昆明医科大学学报.
[12]	李丹娜, 杨明莹, 王俊, 王留芳, 吴光柳, 王会笑, 陈奖国, 姚呈, 黄应龙. 膀胱全切原位尿流改道术患者生命质量下降的术前危险因素, 昆明医科大学学报.
[13]	雷玉英, 高洁, 王饶祥, 钏莉雪, 郝金钢. 弥散加权成像在膀胱癌诊断的价值, 昆明医科大学学报.
[14]	黄振华, 石鑫, 王辉涛, 张劲松, 王光, 郝金刚, 刘建和. 磁共振弥散加权成像在膀胱癌T分期的应用价值, 昆明医科大学学报.
[15]	胡新一. 3D腹腔镜根治性膀胱切除、回肠原位尿流改道术, 昆明医科大学学报.
[16]	张劲松. 保留前列腺的根治性膀胱切除治疗肌层浸润性膀胱癌的适应症, 昆明医科大学学报.
[17]	马真. 改良型TAT-VP3融合蛋白对膀胱癌BIU-87细胞Bcl-2和Survivin表达的影响, 昆明医科大学学报.
[18]	. 膀胱全切回肠代膀胱术后并发下肢静脉血栓2例护理体会, 昆明医科大学学报.
[19]	. 肌层浸润性膀胱癌的治疗策略, 昆明医科大学学报.
[20]	杨明莹. 膀胱全切原位新膀胱术围手术期健康教育的实施与应用, 昆明医科大学学报.